Loading
AZD7789 is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, aimed at PD-1 and TIM-3.
AZD7789 is a bispecific antibody developed by AstraZeneca. Its targets are PD-1 and TIM-3 (the sponsor names PD-1 x TIM-3). The sponsor states: An anti-PD-1 and anti-TIM-3 bispecific antibody that simultaneously engages both immune checkpoints to enhance anti-tumour immunity. ClinicalTrials.gov describes the intervention as: anti-PD-1 and anti-TIM-3 bispecific antibody. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer. The largest, NCT04931654, plans to enrol 136 participants (actual) with primary completion was scheduled for 2024-12-04 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.One arm of AZD7789 binds PD-1 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD7789" OR ABSTRACT:"AZD7789") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD7789, not a curated reading list.
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1-high gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.